Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Department of Human Genetics, University of Michigan Medical School, Ann Arbor.
Hemophilia B, one of two common hereditary bleeding disorders, is caused by a deficiency of factor IX in the circulation. Molecular mechanisms of hemophilia B are highly heterogeneous including gene deletions, insertions, complex rearrangements, and a large number of point mutations. Currently, hemophilia B is treated by plasma protein replacement therapy. This therapy is effective but exposes patients to possible side effects and complications such as infection of blood-borne pathogens including hepatitis viruses and HIV-1. Intensive efforts to develop alternative, safer therapies for hemophilia B, including somatic gene therapy, are now under way.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on